Refractory Vulvovaginal Lichen Planus Responding to Oral Tofacitinib
Australasian Journal of Dermatology · 2025
DOI: 10.1111/ajd.14403 ↗Kurz gefasst
Fallbericht in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Benetta Benny und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, All India Institute of Medical Sciences, Jodhpur, India. Hauptthemen laut MEDLINE: Lichen Planus, Piperidines, Protein Kinase Inhibitors, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Erosive vulvovaginal lichen planus is a severe form of Lichen planus (LP) that can result in chronic scarring if not treated. It can cause narrowing of the introitus, resulting in pain, itch, dyspareunia, dysuria, and recurrent urinary tract infections caused by retention of urine. Therefore, an effective and safer therapeutic approach is required. Here, we present a case of refractory erosive vulvovaginal LP, which showed remarkable response to oral tofacitinib, a Janus kinase 1 and 3 (JAK1/3) inhibitor, which was well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, All India Institute of Medical Sciences, Jodhpur, India.
- Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, India.
ORCID-Profile: Benetta Benny
Zitieren
APA
Benny, B., Bains, A., & Nalwa, A. (2025). Refractory Vulvovaginal Lichen Planus Responding to Oral Tofacitinib. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14403
Vancouver
Benny B, Bains A, Nalwa A. Refractory Vulvovaginal Lichen Planus Responding to Oral Tofacitinib. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.14403
BibTeX
@article{Benny2025,
author = {Benny, Benetta and Bains, Anupama and Nalwa, Aasma},
title = {Refractory Vulvovaginal Lichen Planus Responding to Oral Tofacitinib},
journal = {Australasian Journal of Dermatology},
year = {2025},
doi = {10.1111/ajd.14403}
}
EUVIMED